je.st
news
Tag: merck
Exclusive: Merck in final talks to sell consumer unit for near $14 billion - sources
2014-04-27 07:42:34| Chemicals - Topix.net
Merck & Co Inc is in the final stages of selling its consumer healthcare unit for close to $14 billion, with Bayer AG and Reckitt Benckiser Group Plc among final contenders to clinch a deal as soon as next week, people familiar with the matter said.
Merck and Award-Winning Actress S. Epatha Merkerson Challenge Americans with Type 2 Diabetes to Get to Their Goals
2014-04-23 16:33:30| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Stage and Screen Star Shines a Spotlight on Better Blood Sugar Management With Americas Diabetes Challenge: Get to Your Goals Program Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it is teaming up with Emmy and Golden Globe-winning actress S. Epatha Merkerson on Americas Diabetes Challenge: Get to Your Goals, an educational program intended to encourage people with type 2 diabetes to achieve better control of their blood sugara key goal to help reduce the risk of serious health problems. Language: English Multimedia read more
FDA OKs Merck Tablet to Reduce Ragweed Allergies
2014-04-18 00:15:25| Biotech - Topix.net
U.S. regulators have again approved a Merck & Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen.
Tags: reduce
tablet
fda
allergies
Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Nave Patients with Genotype 1 Infection
2014-04-10 07:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Clinical Findings Support Advancement into Phase 3 Trials WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639Sarra Herzog, 201-669-6570orInvestors:Carol Ferguson, 908-500-1101Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
results
studies
patients
Merck wants to test Zilmax on 240,000 cattle but beef industry resists
2014-04-05 17:17:50| Food - Topix.net
Merck & Co Inc wants to feed its controversial feed additive Zilmax to 240,000 U.S. cattle to prove it is safe.
Tags: test
industry
beef
cattle
Sites : [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] next »